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The EGF A61G Polymorphism Is Associated with
Disease-Free Period and Survival in Malignant
Melanoma
Ichiro Okamoto1, Florian Roka1, Julia Kro¨gler1, Georg Endler2, Stefan Kaufmann1, Silvia Tockner1,2,
Claudia Marsik2, Bernd Jilma3, Christine Mannhalter2, Oswald Wagner2 and Hubert Pehamberger1
An earlier study reported that a common polymorphism in the 50 untranslated region of the epidermal growth
factor (EGF) gene is associated with increased risk for cutaneous malignant melanoma (MM) and Breslow
thickness. Since then, several independent studies have reported conflicting results that have challenged this
hypothesis. However, none of the previous studies examined survival as the primary outcome. We therefore
sought to study the association between this polymorphism and survival. One hundred and thirty patients
diagnosed with MM with a Breslow thickness of 41.5 mm were included in this study. In our collective, the G/G
genotype represented a significant risk factor for both shorter disease-free period (hazard ratio of 2.246, 95% CI:
1.06–4.78, P¼ 0.036) and overall MM-specific survival (hazard ratio of 3.8, 95% CI: 1.5–9.5, P¼ 0.004) compared
with the A/A genotype, while the heterozygous A/G genotype showed an intermediate risk. In the present study,
we demonstrate for the first time that the EGF A61G polymorphism is associated with survival. Our data suggest
that this polymorphism is a potential marker for disease severity that predicts earlier progression of MM.
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INTRODUCTION
After excision of the primary tumor, the occurrence of lymph
node metastasis is the first clinically discernable sign of
progressive disease in the majority of malignant melanoma
(MM) cases (Balch et al., 2003). MM with systemic
involvement is effectively incurable due to its aggressive
growth and resistance to apoptosis (Roka et al., 2005). Tumor
thickness, according to Breslow, is still the primary prog-
nostic factor at initial diagnosis (Balch et al., 2001). Relatively
little is known about the molecular factors that mediate
growth and survival of MM in vitro and in vivo, although
recently an increasing body of evidence has emerged
supporting the mitogen-activated protein kinase pathway as
being involved in the oncogenic growth of this tumor
(Bardeesy et al., 2005). Mutational and functional analysis
support the idea that epidermal growth factor (EGF), encoded
by a single gene at locus 4q25–27, operates through this
pathway via RAS and BRAF in melanocytic tumors (Mattei
et al., 1994).
A recent study showed that a single nucleotide poly-
morphism (SNP) located in the 50 untranslated region at
position 61 influences the expression level of EGF in
peripheral blood mononuclear cells (Shahbazi et al., 2002).
Moreover, Shahbazi et al. demonstrated not only a significant
association between homozygosity for the EGF 61*G allele
and melanoma incidence (odds ratio (OR), 4.9; 95% CI;
2.3–10.2) but also a correlation with Breslow thickness,
suggesting that the polymorphism might play a role as a
prognostic marker. However, conflicting findings have
challenged this hypothesis so far. (McCarron et al., 2003;
Amend et al., 2004; James et al., 2004; Randerson-Moor
et al., 2004), except for one study confirming a marginal
association of the G/G genotype with Breslow thickness
(McCarron et al., 2003).
As the proposed effect of the EGF polymorphism on
disease progression has been evaluated by assessing Breslow
thickness but not survival, we hypothesized that the tumor
promoting effect of the EGF 61*G allele might become more
evident when disease severity is assessed during follow up
after excision of the primary tumor. We thus examined the
functional relevance and predictive value of the EGF A61G
variant in the clinical course of MM patients by investigating
the association of this SNP with disease free and melanoma
specific over all survival.
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RESULTS
Genotype frequencies of the EGF 50 untranslated region variant
A61G
The overall genotype frequencies of the EGF A61G variant
within the study group did not differ significantly from those
previously reported in other Caucasian control populations
(Shahbazi et al., 2002; McCarron et al., 2003; James et al.,
2004; Randerson-Moor et al., 2004): 45 (34.6%) of the
patients were A/A, 65 (50%) were heterozygous A/G, and 20
(15.4%) were homozygous for the G/G genotype (Table 1).
Therefore, in accordance with the majority of previously
reported data (McCarron et al., 2003; James et al., 2004;
Randerson-Moor et al., 2004) our findings did not support the
hypothesis that the EGF A61G promoter polymorphism was a
potential risk factor for acquiring incident MM in our study
population. Clinical and patient characteristics are presented
in Table 2.
Association of the EGF genotype with Breslow thickness and
disease-free period
With regard to Breslow thickness, we detected a trend for the
G/G homozygous individuals to have thinner MM (2.8 mm
(71.5) compared to 3.4 mm (71.9) in A/G, and 3.4 mm
(71.9) in A/A individuals), although this finding was not
statistically significant (Table 2). We then assessed the
potential role of the EGF polymorphism as a prognostic
factor for disease-free period in a multivariate cox regression
model adjusted for sex, age, and Breslow thickness as
covariates. Of the 130 patients, 69 (53%) progressed from
stage II to III (regional lymph node metastasis) within the
observation period (mean 59 months 747). Twenty four
patients without any signs of relapse were lost to follow-up,
whereas nine patients died of other causes than MM. In
addition to tumor thickness, which represented the strongest
prognostic factor for outcome, the EGF 61 G/G genotype
represented a significant risk factor for shorter disease-free
period with a hazard ratio of 2.246 (95% CI: 1.06–4.78,
P¼0.036, Table 3) compared with A/A carriers, whereas the
heterozygous EGF 61 A/G genotype appeared to have an
intermediate risk for metastasis (hazard ratio: 1.541 (95% CI:
0.87–2.70), P¼ 0.13, Table 3a, Figure 1a).
Association of EGF genotype with MM-specific survival
Within the observation period (mean 10.1. years74.4 years)
a total of 48 patients died, of whom nine had to be censored
due to death of other causes than melanoma. In parallel with
disease-free survival, the G/G and the A/G genotype was
significantly associated with shorter melanoma-specific
survival. Compared to EGF A/A carriers, individuals with
the homozygous EGF G/G genotype had a hazard ratio of 3.8
(95% CI: 1.5–9.5, P¼0.004) of dying due to melanoma,
whereas heterozygous EGF G/A individuals showed again an
Table 1. Genotypes and allele frequencies (percentages) in Caucasian control populations and cases in the present
study
Shahbazi
et al., 2002
McCarron
et al., 2003
Amend
et al., 2004
James
et al., 2004
Randerson-Moor
et al., 2004 Present study
Total 99 310 232 2,646 669 130
A/A 32 (32.3) 121 (39) 84 (36.2) 883 (33.4) 219 (32.8) 45 (34.6)
A/G 47 (47.5) 131 (42.3) 118 (50.9) 1,317 (49.8) 338 (50.5) 65 (50)
G/G 20 (20.2) 58 (18.7) 30 (12.9) 446 (16.9) 112 (16.7) 20 (15.4)
A allele 111 (56.1) 273 (60.2) 286 (61.6) 3,083 (58.3) 776 (58) 155 (59.6)
G allele 87 (43.9) 247 (39.8) 178 (38.4) 2,209 (41.7) 562 (42) 105 (40.4)
Table 2. Clinical characteristics and EGF genotype distributions of patients with MM
Total A/A A/G G/G P-value
N1 130 (100%) 45 (34.6%) 65 (50%) 20 (15.4%)
Age (7SD) in years2 56.6 (714.6) 58.3 (714.2) 57.4 (712.6) 50.4 (719.7) 0.7
Females1 60 (46%) 20 (44%) 30 (46%) 10 (50%) 0.9
Breslow thickness (mm) (7SD)2 3.3 (71.7) 3.4 (71.9) 3.3 (71.6) 2.8 (71.5) 0.5
Patients who developed metastases1 69 (53%) 19 (42%) 38 (58%) 12 (60%) 0.2
Patients who died from melanoma1 39 (30%) 9 (20%) 20 (31%) 10 (60%) 0.05
1Categorical variables are given as counts and percentages.
2Continuous variables are given as means (7SD).
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intermediate risk (hazard ratio: 1.4, 95% CI: 0.7–3.2, Table
3b, Figure 1b).
DISCUSSION
We describe here for the first time a significant association
between the high-expression homozygous G/G genotype of
the EGF gene and shorter disease-free period and MM-
specific survival compared to A/G and A/A carriers. This
finding confirms the prognostic value of the EGF A61G SNP
in MM which was originally proposed by Shahbazi et al.
Moreover, the G/G genotype had the highest risk for
metastasis with 60% (12/20) becoming metastatic compared
to 58% in A/G and 42% in A/A individuals (Table 2),
although this observation was not statistically significant.
With regards to Breslow thickness, we did not find a notable
association between the EGF A61G variants and tumor
thickness, which is in agreement with the majority of
previously published reports (Amend et al., 2004; James
et al., 2004; Randerson-Moor et al., 2004).
This finding of null association of the EGF A61G SNP and
Breslow thickness together with the observed shorter disease-
free survival in G/G individuals appears paradoxical at first. If
EGF contributes to disease progression in MM, an association
with both Breslow thickness as well as disease-free survival
would be expected. Several molecular studies have shown
that the expression of the receptor for EGF, which is a
membrane bound receptor tyrosine kinase, is higher in
advanced stages of MM than it is in early lesions (Huang
et al., 1996; Udart et al., 2001). As the expression of the EGF
receptor is higher in melanoma metastasis compared with
primary MM (Udart et al., 2001), it seems plausible that the
stimulatory effect of EGF on melanoma cells become more
evident in more advanced stages. Another explanation for the
apparent paradox may be that there is a difference between
an oncogenic mutation which is characteristic of the tumor
and a polymorphism, which is a genomic variant present in
both the tumor and the host. Oncogenic mutations provide
the basis for the pathological character and clonal evolution
of a tumor. Both, the higher expression of the EGF receptor in
advanced stages and the low penetrance of the genetic
variant might explain the long term but clinically relevant
effects during disease progression. Tumor thickness might
thus not be relevant for assessing the tumor-promoting effect
of the EGF A61G SNP. However, the reason for this null
association with Breslow thickness but positive correlation to
disease-free survival still remains to be further elucidated.
MM is known to spread early into the surrounding tissue
and invade both lymphatic and blood vessels (Garbe et al.,
Table 3. (a) Prognostic factors predicting disease free
survival in a multivariate Cox regression and (b)
prognostic factors predicting melanoma-specific
survival in a multivariate Cox regression
P-value Hazard ratio1 95% CI
(a)
EGF 61 A/A — — —
EGF 61 A/G 0.132 1.541 (0.87–2.70)
EGF 61 G/G 0.036 2.246 (1.06–4.78)
Age 0.092 1.015 (0.998–1.03)
Male sex 0.149 1.450 (0.88–2.40)
Breslow thickness 0.004 1.199 (1.06–1.36)
P-value Hazard ratio2 95% CI
(b)
EGF 61 A/A — — —
EGF 61 A/G 0.363 1.45 (0.65–3.20)
EGF 61 G/G 0.004 3.79 (1.51–9.48)
Age 0.113 1.02 (1.00–1.04)
Male sex 0.052 1.97 (0.99–3.90)
Breslow thickness 0.138 1.15 (0.95–1.38)
1Hazard ratios for continuous variables are calculated as increase in risk
per mm of Breslow thickness and age in years, respectively, against the
reference category (EGF 61 A/A).
2Hazard ratios for continuous variables are calculated as increase in risk
per mm of Breslow thickness and age in years, respectively, against the
reference category (EGF 61 A/A). If A/G is taken as reference, the hazard
ratio for G/G is 2.5 (95% CI: 1.1–5.5, P=0.026).
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Figure 1. Survival of MM patients according to EGF genotype. Analysis of
(a) disease-free period and (b) melanoma-specific survival were carried out
according to EGF A61G genotype in a multivariate cox regression adjusted for
sex, age, and Breslow thickness.
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2003; Moehrle et al., 2004; Thomas et al., 2004). To date,
Breslow thickness is the most significant prognostic factor in
MM at the time of diagnosis (Balch et al., 2001). Our data
suggest that the EGF A61G SNP might not only be capable of
predicting the risk for early metastasis of MM but also
disease-specific survival, which confirms the clinical rele-
vance of the molecular biological findings, emphasizing the
role of the mitogen-activated protein kinase pathway via RAS
and BRAF in MM in vitro. However, our study clearly
requires validation in a much larger study group.
MATERIALS AND METHODS
Patients
One hundred and thirty patients (70 male, 60 female; mean age:
56.1 years (714.6 years)) diagnosed with cutaneous MM with a
Breslow thickness of more than 1.5 mm between January 1988 and
December 1995, for whom formalin-fixed tissue for DNA prepara-
tion was available, were included in our study. All patients were
diagnosed by two independent histopathologists at the Department
of Dermatology, Medical University of Vienna. Patient character-
istics are shown in Table 1. Clinical data (including sex, age, and
Breslow thickness) were retrieved from patients’ records. The overall
observation period did not differ significantly between all genotypes
(mean 59 months 747). Disease-free period was determined as the
time between removal of the primary tumor and signs of relapse as
detected and confirmed by either sonography, computed tomogra-
phy, or histopathology after surgical removal according to recent
classifications (Garbe et al., 2003). Melanoma-specific survival was
assessed via record linkage with the Austrian Death registry,
resulting in date of death (if occurred between January 1990 and
December 2004) and cause of death encoded either according to the
International Code of diseases Version 9 (ICD9) before 2002, later on
according to the ICD 10. Before 1990, all patients were regularly
seen in our outpatients unit for follow-up examinations. Death due
to MM was considered present if the cause of death was either
encoded as 1720–1729 (ICD 9) or C43.0–C43.9 (ICD 10),
respectively. The Austrian death registry comprises all deaths within
Austria and the deaths of Austrian residents in foreign countries.
According to Austrian law all deaths have to undergo post mortem, if
the final cause of death is not evident from the patients’ history
resulting in an overall post mortem frequency of 72% in our study.
Thus, we estimate that diagnoses are correct in 95% of all cases. For
statistical analysis only anonymized data were used containing no
personal information except age in years and sex. The study was
approved by the local ethics committee.
DNA extraction and analysis of the EGF 50untranslated region
variant A61G
Genomic DNA was extracted from formalin-fixed, paraffin-em-
bedded tissue blocks as previously described (Ye et al., 2001;
McCarron et al., 2003). Briefly, two to four 20-mm sections were cut
from each tissue block and were dewaxed in xylene (Sigma-Aldrich
Corp., St Louis, MO) and xylene–ethanol washes. DNA was
extracted from the resulting cellular material by proteinase-K
digestion. Genotyping of the EGF (A/G) SNP 61 bp downstream of
the major transcription start position was performed using a
commercially available assay for allelic discrimination based on
the principles of real-time PCR on a Taq Man Thermocycler (Applied
Biosystems, Foster City, CA), as described elsewhere (McCarron
et al., 2003). Two independent researchers who were blinded to the
clinical variables carried out interpretation and documentation of
the results.
Statistical analysis
For statistical analyses the SPSS 10.0. software package (SPSS Inc.,
Chicago, IL) was used. Continuous data are presented as mean and
standard deviation unless otherwise stated. Discrete data are given
as counts and percentages. Univariate analysis was performed using
an unpaired samples Student’s t-test and w2 tests as appropriate.
Variables that were not normally distributed were log transformed
before applying the t-test or analysis of variance as required. The
influence of the EGF genotype on the main outcome variable,
disease-free period, was assessed in the Cox proportional–hazards
regression model adjusting for sex, age, and Breslow thickness. The
assumptions underlying the proportional–hazards model (propor-
tional hazards, lack of interaction, and linearity of continuous
variables) were tested and found valid unless otherwise indicated. A
two-sided P-value o0.05 was considered statistically significant.
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